Updated on: Apr 19, 2012

Surya Pharmaceutical Ltd has informed BSE that: 1. The State Bank of India as the lead bank of the consortium of bankers of Surya Pharmaceutical Limited has referred the Company for restructuring of its debt to the Corporate Debt Restructuring Cell, Mumbai and the Company has been admitted by CDR Cell with the support of majority of lenders; 2. The Company has received Certificate of Suitability (COS) for Cefalexin Monohydrate from European Directorate for the Quality of Medicines (EDQM), in addition to already approved Cefixime. Further, the Companys Banur Plant has also been approved by Teva for the supply of Intermediates. These developments and the expected approvals from USFDA/TGA/MCA/MCC will help the Company service its debt obligation post restructuring.

Source : BSE - >www.bseindia.com

Published on November 15, 2017

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like

Recommended for you